CoChat
Sign Up
Cited by 224SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Open access
Yong, Chean Yeah, Ong, Hui Kian, Yeap, Swee Keong, Ho, Kok Lian, Tan, Wen Siang·2019·Frontiers in Microbiology
DOI 10.3389/fmicb.2019.01781PMC PMC6688523
Open this paper in CoChat — free accountOpen PDF

Abstract

Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2019.01781

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous reports on SARS and MERS vaccine candidates raised concerns about pulmonary immunopathology caused by Th2 response or ADE.

    “Previous reports on the development of SARS and MERS vaccine candidates raised concerns about pulmonary immunopathology, either directly caused by a type 2 helper T-cell (Th2) response or as a result of ADE (4, 14, 15).”

    From Development of an inactivated vaccine candidate for SARS-CoV-2 (2020) · cites this paper as [15]

    The ‘Potential Antibody Dependent Enhancement (ADE) of Mers-CoV Infection’ section describes ADE as a vaccine-safety concern, reports adverse inflammatory responses in animals given SARS vaccine candidates, and says no ADE had been observed for MERS-CoV. The ‘Criteria for an Effective Mers-CoV Vaccine’ section reports Th2-biased responses to a MERS vaccine formulation, but does not link Th2 responses or ADE to pulmonary immunopathology. The specific lung-pathology mechanism in the claim is therefore not supported by this copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 132 · Cited by 224

Research works printed but not linked: 123

  1. Adney D. R. van Doremalen N. Brown V. R. Bushmaker T. Scott D. de Wit E. (2014). Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 20 1999– 2005. 10.3201/eid2012.141280 25418529 PMC4257817 · DOI
  2. Adney D. R. Wang L. van Doremalen N. Shi W. Zhang Y. Kong W. P. (2019). Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 11: E212. 10.3390/v11030212 30832356 PMC6466352 · DOI
  3. Agnihothram S. Gopal R. Yount B. L. Jr. Donaldson E. F. Menachery V. D. Graham R. L. (2014). Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J. Infect Dis. 209 995– 1006. 10.1093/infdis/jit609 24253287 PMC3952667 · DOI
  4. Agrawal A. S. Garron T. Tao X. Peng B. H. Wakamiya M. Chan T. S. (2015). Generation of a transgenic mouse model of middle east respiratory syndrome coronavirus infection and disease. J. Virol. 89 3659– 3670. 10.1128/JVI.03427-3414 25589660 PMC4403411 · DOI
  5. Agrawal A. S. Tao X. Algaissi A. Garron T. Narayanan K. Peng B. H. (2016). Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12 2351– 2356. 10.1080/21645515.2016.1177688 27269431 PMC5027702 · DOI
  6. Al-Amri S. S. Abbas A. T. Siddiq L. A. Alghamdi A. Sanki M. A. Al-Muhanna M. K. (2017). Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci. Rep. 7: 44875. 10.1038/srep44875 28332568 PMC5362948 · DOI
  7. Alagaili A. N. Briese T. Mishra N. Kapoor V. Sameroff S. C. Burbelo P. D. (2014). Middle east respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 5: e00884-e14. 10.1128/mBio.00884-14 24570370 PMC3940034 · DOI
  8. Alharbi N. K. Padron-Regalado E. Thompson C. P. Kupke A. Wells D. Sloan M. A. (2017). ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35 3780– 3788. 10.1016/j.vaccine.2017.05.032 28579232 PMC5516308 · DOI
  9. Almazan F. DeDiego M. L. Sola I. Zuniga S. Nieto-Torres J. L. Marquez-Jurado S. (2013). Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate. MBio 4: e00650-13. 10.1128/mBio.00650-13 24023385 PMC3774192 · DOI
  10. Baseler L. J. Falzarano D. Scott D. P. Rosenke R. Thomas T. Munster V. J. (2016). An acute immune response to middle east respiratory syndrome coronavirus replication contributes to viral pathogenicity. Am. J. Pathol. 186 630– 638. 10.1016/j.ajpath.2015.10.025 26724387 PMC4816712 · DOI
  11. Bodmer B. S. Fiedler A. H. Hanauer J. R. H. Prufer S. Muhlebach M. D. (2018). Live-attenuated bivalent measles virus-derived vaccines targeting middle east respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virol 521 99– 107. 10.1016/j.virol.2018.05.028 29902727 PMC7118890 · DOI
  12. Bukreyev A. Lamirande E. W. Buchholz U. J. Vogel L. N. Elkins W. R. St Claire M. (2004). Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 2122– 2127. 10.1016/s0140-6736(04)16501-x 15220033 PMC7112367 · DOI
  13. Carrion R. Jr. Patterson J. L. (2012). An animal model that reflects human disease: the common marmoset (Callithrix jacchus). Curr. Opi. Virol. 2 357– 362. 10.1016/j.coviro.2012.02.007 22709521 PMC3378983 · DOI
  14. Cauchemez S. Nouvellet P. Cori A. Jombart T. Garske T. Clapham H. (2016). Unraveling the drivers of MERS-CoV transmission. Proc. Natl. Acad. Sci. U.S.A. 113 9081– 9086. 10.1073/pnas.1519235113 27457935 PMC4987807 · DOI
  15. Chan J. F. Yao Y. Yeung M. L. Deng W. Bao L. Jia L. (2015). Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 1904– 1913. 10.1093/infdis/jiv392 26198719 PMC7107395 · DOI
  16. Channappanavar R. Zhao J. Perlman S. (2014). T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 59 118– 128. 10.1007/s12026-014-8534-z 24845462 PMC4125530 · DOI · Paper page
  17. Chen Z. Bao L. Chen C. Zou T. Xue Y. Li F. (2017). Human neutralizing monoclonal antibody inhibition of middle east respiratory syndrome coronavirus replication in the common marmoset. J. Infect. Dis. 215 1807– 1815. 10.1093/infdis/jix209 28472421 PMC7107363 · DOI
  18. Chi H. Zheng X. Wang X. Wang C. Wang H. Gai W. (2017). DNA vaccine encoding middle east respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 35 2069– 2075. 10.1016/j.vaccine.2017.02.063 28314561 PMC5411280 · DOI
  19. Chowell G. Abdirizak F. Lee S. Lee J. Jung E. Nishiura H. (2015). Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med. 13: 210. 10.1186/s12916-015-0450-450 26336062 PMC4558759 · DOI
  20. Chu D. K. Poon L. L. Gomaa M. M. Shehata M. M. Perera R. A. Abu Zeid D. (2014). MERS coronaviruses in dromedary camels, Egypt. Emerg. Infect. Dis. 20 1049– 1053. 10.3201/eid2006.140299 24856660 PMC4036765 · DOI
  21. Chu H. Zhou J. Wong B. H. Li C. Cheng Z. S. Lin X. (2014). Productive replication of middle east respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virol 454-455 197– 205. 10.1016/j.virol.2014.02.018 24725946 PMC7111975 · DOI
  22. Cockrell A. S. Yount B. L. Scobey T. Jensen K. Douglas M. Beall A. (2016). A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol. 2: 16226. 10.1038/nmicrobiol.2016.226 27892925 PMC5578707 · DOI
  23. Coleman C. M. Liu Y. V. Mu H. Taylor J. K. Massare M. Flyer D. C. (2014). Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32 3169– 3174. 10.1016/j.vaccine.2014.04.016 24736006 PMC4058772 · DOI
  24. Coleman C. M. Venkataraman T. Liu Y. V. Glenn G. M. Smith G. E. Flyer D. C. (2017). MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35 1586– 1589. 10.1016/j.vaccine.2017.02.012 28237499 PMC5423355 · DOI
  25. de Wit E. Feldmann F. Horne E. Okumura A. Cameroni E. Haddock E. (2019). Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. Antiviral. Res. 163 70– 74. 10.1016/j.antiviral.2019.01.016 30684561 PMC7113761 · DOI
  26. de Wit E. Rasmussen A. L. Falzarano D. Bushmaker T. Feldmann F. Brining D. L. (2013). Middle east respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 110 16598– 16603. 10.1073/pnas.1310744110 24062443 PMC3799368 · DOI
  27. Deng Y. Lan J. Bao L. Huang B. Ye F. Chen Y. (2018). Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg. Microbes. Infect. 7: 60. 10.1038/s41426-018-0056-57 29618723 PMC5884803 · DOI
  28. DeZure A. D. Berkowitz N. M. Graham B. S. Ledgerwood J. E. (2016). Whole-Inactivated and virus-like particle vaccine strategies for chikungunya virus. J. Infect. Dis. 214(suppl. 5), S497– S499. 10.1093/infdis/jiw352 27920180 PMC5137244 · DOI
  29. Dicks M. D. J. Spencer A. J. Edwards N. J. Wadell G. Bojang K. Gilbert S. C. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7: e40385. 10.1371/journal.pone.0040385 22808149 PMC3396660 · DOI
  30. Du L. Jiang S. (2015). Middle east respiratory syndrome: current status and future prospects for vaccine development. Exp. Opin. Biol. Ther. 15 1647– 1651. 10.1517/14712598.2015.1092518 26414077 PMC4636333 · DOI
  31. Du L. Kou Z. Ma C. Tao X. Wang L. Zhao G. (2013). A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8: e81587. 10.1371/journal.pone.0081587 24324708 PMC3852489 · DOI
  32. Du L. Tai W. Yang Y. Zhao G. Zhu Q. Sun S. (2016a). Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7: 13473. 10.1038/ncomms13473 27874853 PMC5121417 · DOI
  33. Du L. Tai W. Zhou Y. Jiang S. (2016b). Vaccines for the prevention against the threat of MERS-CoV. Expert. Rev. Vaccines 15 1123– 1134. 10.1586/14760584.2016.1167603 26985862 PMC5097835 · DOI
  34. Dutry I. Yen H. L. Lee H. Peiris M. Jaume M. (2011). Antibody-dependent enhancement (ADE) of infection and its possible role in the pathogenesis of influenza. BMC Proc. 5(Suppl. 1): P62 10.1186/1753-6561-5-S1-P62 · DOI
  35. Falzarano D. de Wit E. Feldmann F. Rasmussen A. L. Okumura A. Peng X. (2014). Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10: e1004250. 10.1371/journal.ppat.1004250 25144235 PMC4140844 · DOI
  36. Fan C. Wu X. Liu Q. Li Q. Liu S. Lu J. (2018). A human DPP4-knockin mouse’s susceptibility to infection by authentic and pseudotyped MERS-CoV. Viruses 10: E448. 10.3390/v10090448 30142928 PMC6164841 · DOI
  37. Fausther-Bovendo H. Kobinger G. P. (2014). Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum. Vaccines Immunother. 10 2875– 2884. 10.4161/hv.29594 25483662 PMC5443060 · DOI
  38. Ferraro B. Morrow M. P. Hutnick N. A. Shin T. H. Lucke C. E. Weiner D. B. (2011). Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53 296– 302. 10.1093/cid/cir334 21765081 PMC3202319 · DOI
  39. Fett C. DeDiego M. L. Regla-Nava J. A. Enjuanes L. Perlman S. (2013). Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 87 6551– 6559. 10.1128/jvi.00087-13 23576515 PMC3676143 · DOI
  40. Gerdts V. Littel-van den Hurk S. V. D. Griebel P. J. Babiuk L. A. (2007). Use of animal models in the development of human vaccines. Future Microbio. 2 667– 675. 10.2217/17460913.2.6.667 18041907 · DOI
  41. Gerdts V. Wilson H. L. Meurens F. van Drunen Littel-van den Hurk S. Wilson D. Walker S. (2015). Large animal models for vaccine development and testing. ILAR J. 56 53– 62. 10.1093/ilar/ilv009 25991698 · DOI
  42. Goldstein S. A. Weiss S. R. (2017). Origins and pathogenesis of middle east respiratory syndrome-associated coronavirus: recent advances. F1000Res 6: 1628. 10.12688/f1000research.11827.1 29026532 PMC5583735 · DOI
  43. Gossner C. Danielson N. Gervelmeyer A. Berthe F. Faye B. Kaasik Aaslav K. (2016). Human-dromedary camel interactions and the risk of acquiring zoonotic middle east respiratory syndrome coronavirus infection. Zoonoses Public Health 63 1– 9. 10.1111/zph.12171 25545147 PMC7165574 · DOI
  44. Guo X. Deng Y. Chen H. Lan J. Wang W. Zou X. (2015). Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145 476– 484. 10.1111/imm.12462 25762305 PMC4515128 · DOI
  45. Haagmans B. L. van den Brand J. M. Provacia L. B. Raj V. S. Stittelaar K. J. Getu S. (2015). Asymptomatic middle east respiratory syndrome coronavirus infection in rabbits. J. Virol. 89 6131– 6135. 10.1128/JVI.00661-615 25810539 PMC4442453 · DOI
  46. Haagmans B. L. van den Brand J. M. Raj V. S. Volz A. Wohlsein P. Smits S. L. (2016). An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 77– 81. 10.1126/science.aad1283 26678878 · DOI
  47. Hakoum M. B. Jouni N. Abou-Jaoude E. A. Hasbani D. J. Abou-Jaoude E. A. Lopes L. C. (2017). Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open 7: e015997. 10.1136/bmjopen-2017-015997 28982811 PMC5639984 · DOI
  48. Hashem A. M. Algaissi A. Agrawal A. Al-Amri S. S. Alhabbab R. Y. Sohrab S. S. (2019). A highly immunogenic, protective and safe adenovirus-based vaccine expressing MERS-CoV S1-CD40L fusion protein in transgenic human DPP4 mouse model. J. Infect. Dis. 26: jiz137. 10.1093/infdis/jiz137 30911758 PMC7107499 · DOI
  49. He Y. Li J. Li W. Lustigman S. Farzan M. Jiang S. (2006). Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176 6085– 6092. 10.4049/jimmunol.176.10.6085 16670317 · DOI
  50. Jaume M. Yip M. S. Kam Y. W. Cheung C. Y. Kien F. Roberts A. (2012). SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31– 36. 22311359
  51. Jiaming L. Yanfeng Y. Yao D. Yawei H. Linlin B. Baoying H. (2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 35 10– 18. 10.1016/j.vaccine.2016.11.064 27899228 PMC7115548 · DOI
  52. Jung S. Y. Kang K. W. Lee E. Y. Seo D. W. Kim H. L. Kim H. (2018). Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against middle east respiratory syndrome coronavirus. Vaccine 36 3468– 3476. 10.1016/j.vaccine.2018.04.082 29739720 PMC7115429 · DOI
  53. Kaech S. M. Ahmed R. (2001). Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat. Immunol. 2 415– 422. 10.1038/87720 11323695 PMC3760150 · DOI
  54. Kam Y. W. Kien F. Roberts A. Cheung Y. C. Lamirande E. W. Vogel L. (2007). Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 25 729– 740. 10.1016/j.vaccine.2006.08.011 17049691 PMC7115629 · DOI
  55. Kim E. Okada K. Kenniston T. Raj V. S. AlHajri M. M. Farag E. A. (2014). Immunogenicity of an adenoviral-based middle east respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 32 5975– 5982. 10.1016/j.vaccine.2014.08.058 25192975 PMC7115510 · DOI
  56. Kim Y. S. Son A. Kim J. Kwon S. B. Kim M. H. Kim P. (2018). Chaperna-mediated assembly of ferritin-based middle east respiratory syndrome-coronavirus nanoparticles. Front. Immunol. 9: 1093. 10.3389/fimmu.2018.01093 29868035 PMC5966535 · DOI
  57. Kuzmina N. A. Younan P. Gilchuk P. Santos R. I. Flyak A. I. Ilinykh P. A. (2018). Antibody-dependent enhancement of ebola virus infection by human antibodies isolated from survivors. Cell Rep. 24 1802.e5– 1815.e5. 10.1016/j.celrep.2018.07.035 30110637 PMC6697154 · DOI
  58. Lan J. Deng Y. Chen H. Lu G. Wang W. Guo X. (2014). Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the middle east respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 9: e112602. 10.1371/journal.pone.0112602 25405618 PMC4236105 · DOI
  59. Lan J. Deng Y. Song J. Huang B. Wang W. Tan W. (2018). Significant spike-specific IgG and neutralizing antibodies in mice induced by a novel chimeric virus-iike particle vaccine candidate for middle east respiratory syndrome coronavirus. Virol. Sin. 33 453– 455. 10.1007/s12250-018-0064-68 30374826 PMC6235757 · DOI
  60. Lan J. Yao Y. Deng Y. Chen H. Lu G. Wang W. (2015). Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against middle east respiratory syndrome coronavirus challenge. EBioMedicine 2 1438– 1446. 10.1016/j.ebiom.2015.08.031 26629538 PMC4634622 · DOI
  61. Lauring A. S. Jones J. O. Andino R. (2010). Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28 573– 579. 10.1038/nbt.1635 20531338 PMC2883798 · DOI
  62. Ledwith B. J. Manam S. Troilo P. J. Barnum A. B. Pauley C. J. Griffiths T. G. (2000). Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev. Biol. 104 33– 43. 11713822
  63. Leitner W. W. Ying H. Restifo N. P. (1999). DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18 765– 777. 10.1016/s0264-410x(99)00271-6 10580187 PMC1986720 · DOI
  64. Lin J. T. Zhang J. S. Su N. Xu J. G. Wang N. Chen J. T. (2007). Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 12 1107– 1113. 18018769
  65. Liu R. Q. Ge J. Y. Wang J. L. Shao Y. Zhang H. L. Wang J. L. (2017). Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J. Integrat. Agri. 16 2264– 2273. 10.1016/S2095-3119(17)6166061665 PMC7128255 32288953 · DOI
  66. Liu R. Wang J. Shao Y. Wang X. Zhang H. Shuai L. (2018). A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral. Res. 150 30– 38. 10.1016/j.antiviral.2017.12.007 29246504 PMC7113862 · DOI
  67. Ma C. Li Y. Wang L. Zhao G. Tao X. Tseng C. T. K. (2014a). Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32 2100– 2108. 10.1016/j.vaccine.2014.02.004 24560617 PMC4194189 · DOI
  68. Ma C. Wang L. Tao X. Zhang N. Yang Y. Tseng C. K. (2014b). Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments–the importance of immunofocusing in subunit vaccine design. Vaccine 32 6170– 6176. 10.1016/j.vaccine.2014.08.086 25240756 PMC4194190 · DOI
  69. MacLeod M. K. L. Kappler J. W. Marrack P. (2010). Memory CD4 T cells: generation, reactivation and re-assignment. Immunology 130 10– 15. 10.1111/j.1365-2567.2010.03260.x 20331469 PMC2855788 · DOI
  70. Malczyk A. H. Kupke A. Prufer S. Scheuplein V. A. Hutzler S. Kreuz D. (2015). A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J. Virol. 89 11654– 11667. 10.1128/JVI.01815-1815 26355094 PMC4645655 · DOI
  71. Memish Z. A. Cotten M. Meyer B. Watson S. J. Alsahafi A. J. Al Rabeeah A. A. (2014). Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 20 1012– 1015. 10.3201/eid2006.140402 24857749 PMC4036761 · DOI
  72. Menachery V. D. Gralinski L. E. Mitchell H. D. Dinnon K. H. 3rd Leist S. R. Yount B. L. (2017). Middle east respiratory syndrome coronavirus nonstructural protein 16 Is necessary for interferon resistance and viral pathogenesis. mSphere 2: e00346-17. PMC5687918 29152578
  73. Moss B. Smith G. L. Gerin J. L. Purcell R. H. (1984). Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311 67– 69. 10.1038/311067a0 6472464 · DOI
  74. Munster V. J. de Wit E. Feldmann H. (2013). Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368 1560– 1562. 10.1056/NEJMc1215691 23550601 PMC3815470 · DOI
  75. Munster V. J. Wells D. Lambe T. Wright D. Fischer R. J. Bushmaker T. (2017). Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines 2: 28. 10.1038/s41541-017-0029-21 29263883 PMC5643297 · DOI
  76. Murata K. Lechmann M. Qiao M. Gunji T. Alter H. J. Liang T. J. (2003). Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. U.S.A. 100 6753– 6758. 10.1073/pnas.1131929100 12748380 PMC164519 · DOI
  77. Muthumani K. Falzarano D. Reuschel E.L. Tingey C. Flingai S. Villarreal D.O. (2015). A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against middle east respiratory syndrome coronavirus in nonhuman primates. Sci. Trans. Med. 7: 301ra132. 10.1126/scitranslmed.aac7462 26290414 PMC4573558 · DOI
  78. Nyon M. P. Du L. Tseng C. K. Seid C. A. Pollet J. Naceanceno K. S. (2018). Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine 36 1853– 1862. 10.1016/j.vaccine.2018.02.065 29496347 PMC5860679 · DOI
  79. Oh M. -D. Park W. B. Park S. -W. Choe P. G. Bang J. H. Song K. -H. (2018). Middle east respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J. Int. Med. 33 233– 246. 10.3904/kjim.2018.031 29506344 PMC5840604 · DOI
  80. Okba N. M. Raj V. S. Haagmans B. L. (2017). Middle east respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr. Opin. Virol. 23 49– 58. 10.1016/j.coviro.2017.03.007 28412285 PMC7102752 · DOI
  81. Ong H. K. Tan W. S. Ho K. L. (2017). Virus like particles as a platform for cancer vaccine development. PeerJ 5: e4053. 10.7717/peerj.4053 29158984 PMC5694210 · DOI
  82. Pascal K. E. Coleman C. M. Mujica A. O. Kamat V. Badithe A. Fairhurst J. (2015). Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 112 8738– 8743. 10.1073/pnas.1510830112 26124093 PMC4507189 · DOI
  83. Payne D. C. Iblan I. Rha B. Alqasrawi S. Haddadin A. Al Nsour M. (2016). Persistence of antibodies against middle east respiratory syndrome coronavirus. Emerg. Infect. Dis. 22 1824– 1826. 10.3201/eid2210.160706 27332149 PMC5038413 · DOI
  84. Perlman S. Vijay R. (2016). Middle east respiratory syndrome vaccines. Int. J. Infect. Dis. 47 23– 28. 10.1016/j.ijid.2016.04.008 27062985 PMC4969153 · DOI
  85. Prescott J. Falzarano D. de Wit E. Hardcastle K. Feldmann F. Haddock E. (2018). Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques. Front. Immunol. 9: 205. 10.3389/fimmu.2018.00205 29483914 PMC5816332 · DOI
  86. Quan F. S. Compans R. W. Nguyen H. H. Kang S. M. (2008). Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82 1350– 1359. 10.1128/jvi.01615-1617 18032492 PMC2224423 · DOI
  87. Schindewolf C. Menachery V. D. (2019). Middle east respiratory syndrome vaccine candidates: cautious optimism. Viruses 11: E74. 10.3390/v11010074 30658390 PMC6356267 · DOI
  88. Scobey T. Yount B. L. Sims A. C. Donaldson E. F. Agnihothram S. S. Menachery V. D. (2013). Reverse genetics with a full-length infectious cDNA of the middle east respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 110 16157– 16162. 10.1073/pnas.1311542110 24043791 PMC3791741 · DOI · Paper page
  89. Shi J. Zhang J. Li S. Sun J. Teng Y. Wu M. (2015). Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases. PLoS One 10: e0144475. 10.1371/journal.pone.0144475 26641892 PMC4671582 · DOI
  90. Sibal L. R. Samson K. J. (2001). Nonhuman primates: a critical role in current disease research. ILAR J. 42 74– 84. 10.1093/ilar.42.2.74. 11406709 · DOI
  91. Smith R. (2000). Vaccines and medicines for the world’s poorest. Public-private partnerships seem to be essential. BMJ 320 952– 953. 10.1136/bmj.320.7240.952 10753128 PMC1117893 · DOI
  92. Song F. Fux R. Provacia L. B. Volz A. Eickmann M. Becker S. (2013). Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 87 11950– 11954. 10.1128/JVI.01672-1613 23986586 PMC3807317 · DOI
  93. Srivastava S. Kamthania M. Singh S. Saxena A. K. Sharma N. (2018). Structural basis of development of multi-epitope vaccine against middle east respiratory syndrome using in silico approach. Infect. Drug Resist. 11 2377– 2391. 10.2147/idr.s175114 30538505 PMC6254671 · DOI
  94. Swearengen J. R. (2018). Choosing the right animal model for infectious disease research. Animal Model Exp. Med. 1 100– 108. 10.1002/ame2.12020 30891554 PMC6388060 · DOI
  95. Tai W. Wang Y. Fett C. A. Zhao G. Li F. Perlman S. (2017). Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J. Virol. 91: e01651-16. 10.1128/JVI.01651-1616 27795425 PMC5165220 · DOI
  96. Tai W. Zhao G. Sun S. Guo Y. Wang Y. Tao X. (2016). A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virol 499 375– 382. 10.1016/j.virol.2016.10.005 27750111 PMC5167628 · DOI
  97. Tang F. Quan Y. Xin Z. T. Wrammert J. Ma M. J. Lv H. (2011). Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. 186 7264– 7268. 10.4049/jimmunol.0903490 21576510 · DOI · Paper page
  98. Tang J. Zhang N. Tao X. Zhao G. Guo Y. Tseng C. T. (2015). Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum. Vaccin. Immunother. 11 1244– 1250. 10.1080/21645515.2015.1021527 25874632 PMC4514392 · DOI
  99. Ura T. Okuda K. Shimada M. (2014). Developments in viral vector-based vaccines. Vaccines 2 624– 641. 10.3390/vaccines2030624 26344749 PMC4494222 · DOI
  100. van Boheemen S. de Graaf M. Lauber C. Bestebroer T. M. Raj V. S. Zaki A. M. (2012). Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3: e00473-12 10.1128/mBio.00473-412 PMC3509437 23170002 · DOI
  101. van Doremalen N. Falzarano D. Ying T. de Wit E. Bushmaker T. Feldmann F. (2017). Efficacy of antibody-based therapies against middle east respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res. 143 30– 37. 10.1016/j.antiviral.2017.03.025 28389142 PMC6957253 · DOI
  102. van Doremalen N. Munster V. J. (2015). Animal models of middle east respiratory syndrome coronavirus infection. Antiviral Res. 122 28– 38. 10.1016/j.antiviral.2015.07.005 26192750 PMC4561025 · DOI
  103. Veit S. Jany S. Fux R. Sutter G. Volz A. (2018). CD8+ T cells responding to the middle east respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. Viruses 10: 718. 10.3390/v10120718 30558354 PMC6316859 · DOI
  104. Volz A. Kupke A. Song F. Jany S. Fux R. Shams-Eldin H. (2015). Protective efficacy of recombinant modified vaccinia virus ankara delivering middle east respiratory syndrome coronavirus spike glycoprotein. J. Virol. 89 8651– 8656. 10.1128/JVI.00614-615 26018172 PMC4524222 · DOI
  105. Wang C. Zheng X. Gai W. Wong G. Wang H. Jin H. (2017a). Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 140 55– 61. 10.1016/j.antiviral.2016.12.019 28040513 PMC7113847 · DOI
  106. Wang C. Zheng X. Gai W. Zhao Y. Wang H. Wang H. (2017b). MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 8 12686– 12694. 27050368 PMC5355045
  107. Wang L. Shi W. Joyce M. G. Modjarrad K. Zhang Y. Leung K. (2015a). Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6: 7712. 10.1038/ncomms8712 26218507 PMC4525294 · DOI
  108. Wang Y. Liu D. Shi W. Lu R. Wang W. Zhao Y. (2015b). Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the rirst imported case in China: phylogenetics and coalescence analysis. MBio 6 e1280– 15. 10.1128/mBio.01280-1215 PMC4600111 26350969 · DOI
  109. Wang Y. Tai W. Yang J. Zhao G. Sun S. Tseng C. K. (2017c). Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum. Vaccin. Immunother. 13 1615– 1624. 10.1080/21645515.2017.1296994 28277821 PMC5512770 · DOI
  110. Weingartl H. Czub M. Czub S. Neufeld J. Marszal P. Gren J. (2004). Immunization with modified vaccinia virus ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78: 12672. 10.1128/JVI.78.22.12672-12676.2004 15507655 PMC525089 · DOI
  111. Wirblich C. Coleman C. M. Kurup D. Abraham T. S. Bernbaum J. G. Jahrling P. B. (2017). One-Health: a safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies Virus. J. Virol. 91 e02040-16 PMC5215356 27807241
  112. Xie Q. He X. Yang F. Liu X. Li Y. Liu Y. (2018). Analysis of the genome sequence and prediction of B-Cell epitopes of the envelope protein of middle east respiratory syndrome-coronavirus. IEEE/ACM Trans. Comput. Biol. Bioinf. 15 1344– 1350. 10.1109/tcbb.2017.2702588 28574363 PMC7186043 · DOI
  113. Yang Z. -Y. Kong W. -P. Huang Y. Roberts A. Murphy B. R. Subbarao K. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 561– 564. 10.1038/nature02463 15024391 PMC7095382 · DOI
  114. Yeung M. L. Yao Y. Jia L. Chan J. F. Chan K. H. Cheung K. F. (2016). MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat. Microbiol. 1: 16004. 10.1038/nmicrobiol.2016.4 27572168 PMC7097571 · DOI
  115. Yip M. S. Cheung C. Y. Li P. H. Bruzzone R. Peiris J. S. M. Jaume M. (2011). Investigation of antibody-dependent enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of SARS. BMC Proc. 5(Suppl. 1): P80. 27390007
  116. Yong C. Y. Yeap S. K. Goh Z. H. Ho K. L. Omar A. R. Tan W. S. (2015a). Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-Like particles of prawn nodavirus. Appl. Environ. Microbiol. 81 882– 889. 10.1128/AEM.03695-3614 25416760 PMC4292494 · DOI
  117. Yong C. Y. Yeap S. K. Ho K. L. Omar A. R. Tan W. S. (2015b). Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles. Int. J. Nanomed. 10 2751– 2763. 10.2147/IJN.S77405 25897220 PMC4396508 · DOI
  118. Yu P. Xu Y. Deng W. Bao L. Huang L. Xu Y. (2017). Comparative pathology of rhesus macaque and common marmoset animal models with middle east respiratory syndrome coronavirus. PLoS One 12: e0172093. 10.1371/journal.pone.0172093 28234937 PMC5325479 · DOI
  119. Zaki A. M. Van Boheemen S. Bestebroer T. M. Osterhaus A. D. Fouchier R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367 1814– 1820. 10.1056/NEJMoa121172 23075143 · DOI
  120. Zhang N. Channappanavar R. Ma C. Wang L. Tang J. Garron T. (2016). Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against middle east respiratory syndrome coronavirus. Cell Mol. Immunol. 13 180– 190. 10.1038/cmi.2015.03 25640653 PMC4786625 · DOI
  121. Zhao J. Alshukairi A. N. Baharoon S. A. Ahmed W. A. Bokhari A. A. Nehdi A. M. (2017). Recovery from the middle east respiratory syndrome is associated with antibody and T-cell responses. Sci. Immunol. 2: eaan5393 10.1126/sciimmunol.aan5393 PMC5576145 28778905 · DOI
  122. Zhao J. Li K. Wohlford-Lenane C. Agnihothram S. S. Fett C. Zhao J. (2014). Rapid generation of a mouse model for middle east respiratory syndrome. Proc. Natl. Acad. Sci. U.S.A. 111 4970– 4975. 10.1073/pnas.1323279111 24599590 PMC3977243 · DOI
  123. Zhao J. Zhao J. Mangalam A. K. Channappanavar R. Fett C. Meyerholz D. K. (2016). Airway Memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44 1379– 1391. 10.1016/j.immuni.2016.05.006 27287409 PMC4917442 · DOI · Paper page

Authors
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S.
Affiliations
  • Universiti Putra Malaysia (MY)
  • Xiamen University Malaysia (MY)
Corresponding author
Tan, Wen Siang
ORCID
Venue
Frontiers in Microbiology
Publisher
Frontiers Media SA
Published
2019-08-02
Volume
10
Pages
1781-1781
ISSN
1664-302X (ISSN-L)
DOI
10.3389/fmicb.2019.01781
PMC
PMC6688523
OpenAlex
W2963220452
Cited by
224
References
132
Citations by year
2026: 6 · 2025: 6 · 2024: 9 · 2023: 15 · 2022: 23 · 2021: 50 · 2020: 112 · 2019: 1 · 2018: 1 · 2017: 1
FWCI
6.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
Universiti Putra Malaysia (GP-IPS/2018/9602500)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
MERS-CoV, spike protein, nucleocapsid protein, envelope protein, nsp16, viral vector vaccines, DNA vaccine, subunit vaccine, nanoparticle vaccine, inactivated whole virus vaccine, live attenuated vaccine, antibody-dependent enhancement, immune response, animal models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review